NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Medical Instruments & Supplies · USD

Bausch + Lomb Corporation (BLCO) Stock Analysis

Bausch + Lomb Corporation (BLCO) is a Medical Instruments & Supplies stock listed on NYSE and quoted in US Dollar.

BLCO

$18.04

−$0.10 (−0.55%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BLCO with… →

BLCO Key Statistics

As of Sep 4, 2026
Trading
Open
$17.92
Previous Close
$18.14
Day's Range
17.86–18.17
52-Week Range
13.77–18.92
Volume
414.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.56
Valuation
Market Cap
$6.44B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
16.50
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.89
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.21
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.48
Financials (FY)
Revenue (FY)
$5.10B+6.47%
Net Income (FY)
−$360.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
−3.21%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
357.17M
1-Year Return
+23.65%
Dividend and dates
Earnings Date
October 28, 2026estimated
Avg Volume
404.64K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BLCO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+5.62%
2025−5.43%
2024+5.86%
2023+9.99%
2022 (partial year)−22.45%

As of September 4, 2026.

BLCO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$5.10B−$360.00M−7.1%
2024$4.79B−$317.00M−6.6%
2023$4.15B−$260.00M−6.3%
2022$3.77B$6.00M0.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$5.10B$3.05B$188.00M−$360.00M−7.1%
2024$4.79B$2.92B$206.00M−$317.00M−6.6%
2023$4.15B$2.50B$204.00M−$260.00M−6.3%
2022$3.77B$2.25B$220.00M$6.00M0.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BLCO Valuation vs Medical Instruments & Supplies Median

Median of 55 stocks
MetricBLCOMedical Instruments & Supplies medianvs median
P/S ratio1.213.1762% below
Profit margin−3.21%0.85%4.1 pts below

Medians across 55 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 18 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Bausch + Lomb Corporation (BLCO) is capitalised at $6.44B on the latest close. It is classified in the Medical Instruments & Supplies industry, within the Healthcare sector. The company reports 13,000 employees.

Over the past 52 weeks the price has ranged from $13.77 to $18.92. The most recent close on file for BLCO is $18.04, dated September 4, 2026. That is −$0.10 (−0.55%) against the previous close. The latest close sits 31.06% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $5.10B. That is +6.47% against the prior fiscal year, when revenue was $4.79B. The same year closed with a net loss of $360.00M. Profit margin runs at −3.21%. That is 4.1 percentage points below the Medical Instruments & Supplies median of 0.85%. Earnings per share on a trailing basis come to −0.48.

Across the 4 fiscal years on file, revenue moves from $3.77B in 2022 to $5.10B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 16.5. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.89. The price-to-sales ratio is 1.21. On price-to-sales that is 61.86% below the Medical Instruments & Supplies median of 3.17. The medians here are taken across 55 Medical Instruments & Supplies companies that report the metric.

Over the trailing twelve months the price has returned +23.65%. Across 3 years the annualized return works out at +0.17%. The reported beta is 0.56. Annualized volatility over the trailing 4 years is 37.64%.

Growth & Income

The record shows no dividend for BLCO.

The strongest complete calendar year on file is 2023 at +9.99%; the weakest is 2025 at −5.43%. Of the 3 complete calendar years on file, 2 finished higher. So far in 2026 the price is +5.62%.

Peer Comparison

Bausch + Lomb Corporation (BLCO) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Bausch + Lomb Corporation BLCO $6.44B —
Intuitive Surgical, Inc. ISRG $131.38B 42.4
Becton, Dickinson and Company BDX $50.32B 32.0
Medline Inc. MDLN $49.23B 45.7

The Medical Instruments & Supplies industry average P/E ratio is 35.6x. Bausch + Lomb Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$131.38B

 BDX

Becton, Dickinson and Company

$50.32B

 MDLN

Medline Inc.

$49.23B

 ALC

Alcon Inc.

$34.08B

 RMD

ResMed Inc.

$32.94B

 WST

West Pharmaceutical Services, Inc.

$23.93B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Bausch + Lomb Corporation

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Visit website →